17,261 trials
Complicated Urinary Tract Infections
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 53.7; 53.6; 11.9; 7.1 percentage of participants
Stroke · Ischemic Stroke · Cerebrovascular Accident
Primary: Adherence With Intervention — 93.5; 100 percentage of participants — p=0.058
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 5 Participants
PANS · PANDAS · Obsessive Compulsive Disorder (OCD)
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 29.49; 28.43; 20.53; 23.45 units on a scale
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
Sleep Disorders · Congestion, Nasal
Primary: Change From Baseline in Mean Average Score Using Pittsburgh Insomnia Rating Scale (PIRS) in Q1, Q3, Q17 and Q18 at Day 7 — -0.911; -0.694; -1.032; -1.004 Score on a…
Diabetes Mellitus, Type 2
Primary: Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE), AE Related to Study Medication, AE Leading to Discontinuation and Fatal AE of Death…
Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose (MTD) — NA; NA; NA; NA mcg/Kg
Multiple Myeloma
Primary: The Best Overall Response Rate (ORR) — 11 Participants
Dermatitis, Contact
Primary: Analysis of Bioequivalence: Concordance — 76; 98.0 percentage of agreement
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response Following Principle Investigator Review — 23.2 percentage of participants
Glioblastoma
Primary: Pembrolizumab Maximum Tolerated Dose (MTD) [Cohort A Safety Lead-In] — 200 mg every 3 weeks
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase — 15; 5 Participants
Pain · Peripheral Neuropathy
Primary: Worst of the Pain Scores for the Week Following the First Cycle of Paclitaxel Administration, Paclitaxel-associated Acute Pain Syndrome (P-APS) Pain Score — 2.6; 3.2…
Lung Cancer · Non Small Cell Lung Carcinoma
Primary: Number of Participants With Objective Response Assessed by Independent Review Committee — 2; 8; 1 participants